Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
21.07.23
/
50%
€20.80
Target price
21.07.24
€25.14
Performance (%)
-11.06%
Price
06.05.24
€18.50
Summary
This prediction is currently active. The prediction for Myriad Genetics disappoints with a performance of -11.06%. This prediction currently runs until 21.07.24. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Myriad Genetics | 10.778% | 10.778% |
iShares Core DAX® | 0.476% | -0.039% |
iShares Nasdaq 100 | 1.290% | 0.504% |
iShares Nikkei 225® | 1.300% | -2.135% |
iShares S&P 500 | 0.829% | 0.193% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat